ReviewReviews in endocrine & metabolic disorders2008
Mineral metabolism and bone abnormalities in children with chronic renal failure.
Review in Reviews in endocrine & metabolic disorders, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Interventions for metabolic bone disease in children with chronic kidney disease.The Cochrane database of systematic reviews · 2015Pooled it
- Is high-dose cholecalciferol justified in children with chronic kidney disease who failed low-dose maintenance therapy?Pediatric nephrology (Berlin, Germany) · 2013Trial
- Evaluation of Carotid Intima-Media Thickness and Other Cardiovascular Risk Factors in Children with Chronic Kidney Disease.Journal of clinical practice and research · 2025Article
- Review
- Skeletal status assessment by quantitative ultrasound and bone densitometry in children with different renal conditions.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Article
- X-linked hypophosphatemia and growth.Reviews in endocrine & metabolic disorders · 2017Review
- Parathyroid hormone levels in long-term renal transplant children and adolescents.Pediatric nephrology (Berlin, Germany) · 2011Article
- 1,25(OH)2D3 alters growth plate maturation and bone architecture in young rats with normal renal function.PloS one · 2011Article
- Analyses of muscular mass and function: the impact on bone mineral density and peak muscle mass.Pediatric nephrology (Berlin, Germany) · 2010Review
- Imaging chronic renal disease and renal transplant in children.Pediatric radiology · 2010Review
- Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormalities in mineral metabolism and changes in skeletal histology may contribute to growth impairment in children with chronic renal failure. Hyperphosphatemia, hypocalcemia, metabolic acidosis, alterations in vitamin D and IGF synthesis and parathyroid gland dysfunction play significant roles in the development of secondary hyperparathyroidism and subsequently, bone disease in renal failure. The recent KDIGO conference has made recommendations to consider this as a systemic disorder (chronic kidney disease-mineral bone disorder) and to standardize bone histomorphometry to include bone turnover, mineralization and volume (TMV). The use of DXA to assess bone mass is controversial in children with chronic renal failure. Questions arise regarding the accuracy of bone measurements and difficulty in data interpretation especially in children with renal failure who are not only growth retarded but often have pubertal delay and osteosclerosis. The validity and feasibility of new modalities of skeletal imaging which can detect changes in both trabecular and cortical bone are currently being investigated in children. The management of mineral abnormalities and bone disease in chronic renal failure is multifactorial. To manage hyperphosphatemia, dietary phosphate restriction accompanied by intake of calcium-free and metal-free phosphate binding agents are widely utilized. Vitamin D analogs remain the primary therapy for secondary hyperparathyroidism, although the use of the less hypercalcemic agents is preferred due to concerns of calciphylaxis and vascular calcification. Future clinical studies are needed to evaluate the long-term effects of calcimimetic agents and bisphosphonate therapy in children with chronic renal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.